CRISPR Therapeutics AG Sustainability Profile
CRISPR Therapeutics AG, a pioneering biotechnology company headquartered in Switzerland (CH), is at the forefront of gene editing innovation. Founded in 2013, the company focuses on developing transformative therapies using its proprietary CRISPR/Cas9 technology, which allows for precise modifications to DNA. With a strong presence in Europe and North America, CRISPR Therapeutics is dedicated to addressing serious diseases, particularly in the fields of oncology, regenerative medicine, and genetic disorders. Its lead product candidates, including CTX001 for sickle cell disease and beta-thalassemia, exemplify the unique potential of CRISPR technology to provide curative solutions. Recognised for its significant contributions to the industry, CRISPR Therapeutics AG continues to solidify its market position through strategic partnerships and groundbreaking research, making it a key player in the rapidly evolving landscape of gene editing therapies.
DitchCarbon Score
How does CRISPR Therapeutics AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CRISPR Therapeutics AG's score of 28 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CRISPR Therapeutics AG's reported carbon emissions
CRISPR Therapeutics AG, headquartered in Switzerland (CH), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Consequently, there are no recorded Scope 1, 2, or 3 emissions to analyse. In terms of climate commitments, CRISPR Therapeutics AG has not outlined any formal reduction targets or initiatives. There are no details available regarding Science-Based Targets Initiative (SBTi) commitments or other climate pledges. This lack of publicly available data suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the biotechnology industry increasingly prioritises sustainability, CRISPR Therapeutics AG's future climate commitments will be crucial for aligning with industry standards and expectations.
How Carbon Intensive is CRISPR Therapeutics AG's Industry?
How Carbon Intensive is CRISPR Therapeutics AG's Location?
CRISPR Therapeutics AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
CRISPR Therapeutics AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
